Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, Biocon has informed about the company statement that the U.S. FDA conducted a GMP inspection of our APIs manufacturing facility at Telangana from December 12- December 14, 2018. The inspection concluded without any observations and no Form 483 was issued. The successful inspection of this site reflects the company's strong commitment to quality and cGMP compliance.
The above information is a part of company's filings submitted to BSE.